Hackman Jeffrey S.'s Form 4 filing
Fennec Pharmaceuticals Inc.FENC · filed May 19, 2025
- Accession no.
- 0001415889-25-013673
- Filed
- May 19, 2025
- Trade date
- May 16-19, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $104.6K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hackman Jeffrey S.CIK 0001926254 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Shares | PPurchaseAcquired | +1,035 | $6.75 | +$6,986.25 | 1,035 | Direct | |
| May 19, 2025 | Common Shares | PPurchaseAcquired | +13,965 | $6.99 | +$97,615.35 | 15,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.